Occlutech obtains European CE Mark for its novel PmVSD Occluder

Schaffhausen, Switzerland – Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder. The device is a specifically designed implant indicated for the minimally invasive closure of perimembranous ventricular septal defects…

We use cookies to customize content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. Learn more